hyper-IL-6

**hyper-IL-6** is a recombinant designer cytokine consisting of human interleukin-6 (IL-6) covalently linked via a flexible peptide linker to the soluble human interleukin-6 receptor (sIL-6R)[1][3][4][5]. This fusion protein enables activation of the gp130 receptor on a broad range of cells, including those that do not naturally express membrane-bound IL-6 receptor, thereby mimicking and amplifying IL-6 trans-signaling[1]. hyper-IL-6 has been mainly used as a research reagent and molecular tool to distinguish between IL-6 classic signaling and IL-6 trans-signaling, and to study STAT3 pathway activation and tissue responses in vitro and in vivo[1][3]. In animal studies, it has shown potent protective and pro-regenerative effects, such as protection from ischemia-reperfusion kidney injury and promotion of liver repair, with some effects independent of STAT3 and involving the inhibition of IL-11 signaling[4][5]. Developed originally by Stefan Rose-John and colleagues, it is not approved as a medicine but used in basic research.

Other names

hyper-Interleukin-6hyper-Interleukin6hyper-Interleukin 6